全文获取类型
收费全文 | 251948篇 |
免费 | 42413篇 |
国内免费 | 10209篇 |
专业分类
耳鼻咽喉 | 6170篇 |
儿科学 | 6485篇 |
妇产科学 | 3537篇 |
基础医学 | 14598篇 |
口腔科学 | 3253篇 |
临床医学 | 40044篇 |
内科学 | 61401篇 |
皮肤病学 | 8375篇 |
神经病学 | 19749篇 |
特种医学 | 10265篇 |
外国民族医学 | 48篇 |
外科学 | 51142篇 |
综合类 | 19776篇 |
现状与发展 | 103篇 |
一般理论 | 6篇 |
预防医学 | 14938篇 |
眼科学 | 6075篇 |
药学 | 12240篇 |
97篇 | |
中国医学 | 6047篇 |
肿瘤学 | 20221篇 |
出版年
2024年 | 816篇 |
2023年 | 6091篇 |
2022年 | 4768篇 |
2021年 | 8262篇 |
2020年 | 9829篇 |
2019年 | 5540篇 |
2018年 | 10859篇 |
2017年 | 10641篇 |
2016年 | 11389篇 |
2015年 | 13145篇 |
2014年 | 21265篇 |
2013年 | 20926篇 |
2012年 | 13397篇 |
2011年 | 14046篇 |
2010年 | 16173篇 |
2009年 | 18758篇 |
2008年 | 11251篇 |
2007年 | 9684篇 |
2006年 | 11846篇 |
2005年 | 9070篇 |
2004年 | 6882篇 |
2003年 | 5994篇 |
2002年 | 5457篇 |
2001年 | 6526篇 |
2000年 | 5497篇 |
1999年 | 5541篇 |
1998年 | 5132篇 |
1997年 | 4880篇 |
1996年 | 4370篇 |
1995年 | 4162篇 |
1994年 | 2839篇 |
1993年 | 2100篇 |
1992年 | 2002篇 |
1991年 | 1973篇 |
1990年 | 1532篇 |
1989年 | 1579篇 |
1988年 | 1312篇 |
1987年 | 1119篇 |
1986年 | 1104篇 |
1985年 | 873篇 |
1984年 | 629篇 |
1983年 | 597篇 |
1982年 | 567篇 |
1981年 | 442篇 |
1980年 | 377篇 |
1979年 | 341篇 |
1978年 | 338篇 |
1977年 | 409篇 |
1975年 | 282篇 |
1972年 | 308篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
81.
器官移植术是20世纪出现的针对器官功能衰竭的最有效治疗方法,每年拯救全球超过12万例患者。但供器官短缺的现状,与器官移植技术和辅助药物的发展不匹配,制约了器官移植事业的发展。我国自2015年起已成为全球器官捐献和移植大国之一,2017年公民逝世后器官捐献数量超过5 000例,占全球捐献总量的15%以上。黄洁夫教授总结的器官捐献与移植"中国模式"得到了世界卫生组织、国际移植界的高度重视和充分肯定。本文通过整理全球及各国的器官捐献与移植数据,剖析全球现状与发展趋势,进一步探索我国公民器官捐献的影响因素并提出针对性的应对策略,以期实现我国器官捐献和移植的"自给自足"。 相似文献
82.
83.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
84.
85.
Alexander S. Dakos Ellen M. Walker Huai Jiang Barry E. Stein Benjamin A. Rowland 《The European journal of neuroscience》2019,50(11):3702-3712
Unilateral lesions of visual cortex have the secondary consequence of suppressing visual circuits in the midbrain superior colliculus (SC), collectively producing blindness in contralesional space (“hemianopia”). Recent studies have demonstrated that SC visual responses and contralesional vision can be reinstated by a non‐invasive multisensory training procedure in which spatiotemporally concordant visual‐auditory pairs are repeatedly presented within the blind hemifield. Despite this recovery of visual responsiveness, the loss of visual cortex was expected to result in permanent deficits in that hemifield, especially when visual events in both hemifields compete for attention and access to the brain's visuomotor circuitry. This was evaluated in the present study in a visual choice paradigm in which the two visual hemifields of recovered cats were simultaneously stimulated with equally valent visual targets. Surprisingly, the expected disparity was not found, and some animals even preferred stimuli presented in the previously blind hemifield. This preference persisted across multiple stimulus intensity levels and there was no indication that animals were less aware of cues in the previously blind hemifield than in its spared counterpart. Furthermore, when auditory cues were combined with visual cues, the enhanced performance they produced on a visual task was no greater in the normal than in the previously blind hemifield. These observations suggest that the multisensory rehabilitation paradigm revealed greater inherent visual information processing potential in the previously blind hemifield than was believed possible given the loss of visual cortex. 相似文献
86.
87.
科研作图是展示研究数据的主要形式,也是科研素养的重要体现。口腔医学硕士研究生是接触科学研究的第一站,然而目前的研究生教育环节对科研作图能力缺乏系统性培养,许多研究生在科研作图中存在许多不规范的问题,本文针对这一问题进行初步探讨。本文分析比较了常用作图工具Microsoft Excel、Origin和Graphpad Prism的特点;以学校口腔医学硕士的培养过程为参考,分析目前硕士研究生科研作图方面存在的主要问题及应对策略。发现不同作图软件具有不同的风格特点,当前硕士研究生作图存在风格不统一、拼图不规范、图注不规范等问题,应当根据自身需求合理选择作图工具,提升作图能力。科研作图是科研能力的重要方面,应当加强口腔医学硕士研究生作图能力的培养。 相似文献
88.
89.
90.